Schonfeld Strategic Advisors’s Ocular Therapeutix OCUL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	+10,711	New	+$97.1K	﹤0.01%	2301
2026 Q1	–	Sell	-12,364	Closed	-$150K	–	2532
2025 Q4	$150K	Buy	+12,364	New	+$150K	﹤0.01%	1768
2021 Q4	–	Sell	-11,584	Closed	-$116K	–	2416
2021 Q3	$116K	Sell	11,584 -16,716	-59%	-$188K	﹤0.01%	1899
2021 Q2	$401K	Buy	+28,300	New	+$430K	﹤0.01%	1304
2019 Q1	–	Sell	-15,146	Closed	-$60K	–	1171
2018 Q4	$60K	Buy	+15,146	New	+$83.5K	﹤0.01%	1022
2017 Q2	–	Sell	-169,628	Closed	-$1.57M	–	724
2017 Q1	$1.57M	Sell	169,628 -59,273	-26%	-$494K	0.16%	179
2016 Q4	$1.92M	Buy	228,901 +207,998	+995%	+$1.61M	0.25%	122
2016 Q3	$143K	Buy	20,903 +1,233	+6%	+$7.52K	0.02%	383
2016 Q2	$97K	Buy	+19,670	New	+$195K	0.02%	408

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Schonfeld Strategic Advisors's OCUL Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 10,711 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #2301 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in OCUL as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in OCUL in Q2 2016 and has held it in 9 quarters since. The position peaked at $1.92M in Q4 2016. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Schonfeld Strategic Advisors held 10,711 shares of Ocular Therapeutix worth $105K as of Q2 2026.
Ocular Therapeutix was a new Schonfeld Strategic Advisors position in Q2 2026.
Ocular Therapeutix made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2301 holding.
Schonfeld Strategic Advisors first reported a position in Ocular Therapeutix in Q2 2016 and has held it in 9 quarters since.
Schonfeld Strategic Advisors's Ocular Therapeutix position peaked at $1.92M in Q4 2016.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.